RU2019130167A3 - - Google Patents

Download PDF

Info

Publication number
RU2019130167A3
RU2019130167A3 RU2019130167A RU2019130167A RU2019130167A3 RU 2019130167 A3 RU2019130167 A3 RU 2019130167A3 RU 2019130167 A RU2019130167 A RU 2019130167A RU 2019130167 A RU2019130167 A RU 2019130167A RU 2019130167 A3 RU2019130167 A3 RU 2019130167A3
Authority
RU
Russia
Application number
RU2019130167A
Other versions
RU2019130167A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019130167A publication Critical patent/RU2019130167A/ru
Publication of RU2019130167A3 publication Critical patent/RU2019130167A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18311Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18311Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2019130167A 2017-04-04 2018-04-03 Самосборные белковые наноструктуры, экспонирующие f-белки парамиксовируса и/или пневмовируса, и их применение RU2019130167A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762481331P 2017-04-04 2017-04-04
US62/481,331 2017-04-04
PCT/US2018/025880 WO2018187325A1 (en) 2017-04-04 2018-04-03 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Publications (2)

Publication Number Publication Date
RU2019130167A RU2019130167A (ru) 2021-05-05
RU2019130167A3 true RU2019130167A3 (ru) 2021-12-22

Family

ID=62116943

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019130167A RU2019130167A (ru) 2017-04-04 2018-04-03 Самосборные белковые наноструктуры, экспонирующие f-белки парамиксовируса и/или пневмовируса, и их применение

Country Status (14)

Country Link
US (3) US11192926B2 (ru)
EP (1) EP3606942A1 (ru)
JP (2) JP7168938B2 (ru)
KR (1) KR20190140916A (ru)
CN (3) CN110603262A (ru)
AU (2) AU2018249533C1 (ru)
BR (1) BR112019020661A2 (ru)
CA (1) CA3058794A1 (ru)
IL (1) IL269643A (ru)
MX (2) MX2019011869A (ru)
PH (1) PH12019502276A1 (ru)
RU (1) RU2019130167A (ru)
SG (1) SG11201908999QA (ru)
WO (1) WO2018187325A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
US11771755B2 (en) 2018-02-28 2023-10-03 University Of Washington Self-asssembling nanostructure vaccines
KR20210124272A (ko) 2019-02-08 2021-10-14 더 유에스에이, 애즈 레프리젠티드 바이 더 세크러터리, 디파트먼트 오브 헬스 앤드 휴먼 서비스 나노입자-기반 인플루엔자 바이러스 백신 및 이의 용도
CN114502572A (zh) * 2019-09-04 2022-05-13 华盛顿大学 展示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途
CN110878128A (zh) * 2019-11-04 2020-03-13 中国疾病预防控制中心病毒病预防控制所 一种人呼吸道合胞病毒粘膜疫苗及其制备方法和应用
JP2023513592A (ja) * 2020-02-14 2023-03-31 ユニバーシティ オブ ワシントン ポリペプチド及びそれらの使用(関連出願の相互参照)
CA3182021A1 (en) * 2020-06-09 2021-12-16 Scot R. Shepard Method of assemblying two-component virus-like particle
CN116194460A (zh) * 2020-06-09 2023-05-30 Icosavax股份有限公司 制备病毒样颗粒的方法
CN111991556B (zh) * 2020-10-29 2021-03-02 中山大学 SARS-CoV-2 RBD共轭纳米颗粒疫苗
PE20240133A1 (es) 2020-11-13 2024-01-30 Icosavax Inc Vacuna de nanoparticula a base de proteinas contra metapneumovirus
CN112778404B (zh) * 2021-01-28 2022-11-29 中山大学 一种含EB病毒gHgL蛋白的自组装纳米颗粒及其制备方法与应用
WO2023225562A1 (en) 2022-05-17 2023-11-23 Icosavax, Inc. Multivalent vaccine for paramyxoviruses and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4238904A1 (de) 1992-11-19 1994-05-26 Basf Ag Riboflavin-Synthese in Hefen
JP2000152791A (ja) 1998-11-11 2000-06-06 E I Du Pont De Nemours & Co ルマジンシンターゼおよびリボフラビンシンターゼ
JP2008500364A (ja) 2004-05-25 2008-01-10 キメラコア, インコーポレイテッド 自己集合性ナノ粒子薬物送達システム
US7700720B2 (en) 2004-09-21 2010-04-20 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA2710600C (en) 2007-12-24 2017-06-06 Id Biomedical Corporation Of Quebec Recombinant rsv antigens
WO2010019725A2 (en) 2008-08-12 2010-02-18 Salemme Francis R Node polypeptides for nanostructure assembly
GB0817507D0 (en) 2008-09-24 2008-10-29 Ucl Business Plc Protein cages
LT3067064T (lt) 2008-12-09 2020-09-10 Novavax, Inc. Modifikuoti rsv f baltymai ir jų panaudojimo būdai
US20110200560A1 (en) 2009-05-26 2011-08-18 Massachusetts Institute Of Technology Non-ionic self-assembling peptides and uses thereof
WO2011017835A1 (en) 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
MX340796B (es) 2010-07-07 2016-07-27 Artificial Cell Tech Inc Composiciones y procedimientos antigenicos del virus respiratorio sincitial.
WO2012158613A1 (en) 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens
US9441019B2 (en) 2011-09-23 2016-09-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza hemagglutinin protein-based vaccines
JP2014530010A (ja) 2011-09-30 2014-11-17 ノババックス,インコーポレイテッド 呼吸器合胞体ウイルス用の組み換えナノ粒子rsvfワクチン
EP2766030A4 (en) 2011-10-12 2015-09-16 Univ Washington GP120 GENETICALLY MODIFIED EXTERNAL DOMAIN (EOD) OF HIV AND ASSOCIATED MUTANTS
AU2013245950B2 (en) 2012-04-10 2016-04-21 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
US8969521B2 (en) 2012-04-11 2015-03-03 University Of Washington Through Its Center For Commercialization General method for designing self-assembling protein nanomaterials
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
EA201891945A3 (ru) 2012-08-01 2019-05-31 Бавариан Нордик А/С Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)
US20140141037A1 (en) 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
AU2013349778A1 (en) 2012-11-20 2015-05-28 Glaxosmithkline Biologicals Sa RSV F prefusion trimers
WO2014124301A1 (en) 2013-02-07 2014-08-14 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
KR20220139415A (ko) 2013-03-13 2022-10-14 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 선융합(prefusion) RSV F 단백질 및 이의 용도
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
CA2906960C (en) 2013-03-15 2021-07-20 Xiamen University Epitope of rsv fusion protein and antibody recognizing the epitope
PL2988780T3 (pl) 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
BR112015031509B1 (pt) 2013-06-17 2023-05-09 Janssen Vaccines & Prevention B.V. Polipeptídeo de fusão (f) do vírus sincicial respiratório (rsv) pré- fusão recombinante e composição que o compreende
US20150110825A1 (en) 2013-09-24 2015-04-23 Massachusetts Institute Of Technology Self-assembled nanoparticle vaccines
US20150166610A1 (en) 2013-10-14 2015-06-18 Glaxosmithkline Biologicals, S.A. Recombinant rsv antigens
EP2974739A1 (en) * 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
WO2016109792A2 (en) 2014-12-31 2016-07-07 The Usa, As Represented By The Secretary, Detp. Of Health And Human Services Novel multivalent nanoparticle-based vaccines
WO2016138525A1 (en) 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
US10744193B2 (en) 2015-03-30 2020-08-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic RSV polypeptides
CN107847580B (zh) 2015-07-07 2022-08-12 扬森疫苗与预防公司 针对rsv的疫苗
CA2991540A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion respiratory syncytial sirus polypeptides
US10024198B2 (en) 2015-08-13 2018-07-17 Echogen Power Systems, Llc Heat engine system including an integrated cooling circuit
EP3344290A4 (en) 2015-08-31 2019-02-27 Technovax, Inc. VACCINE BASED ON VIRUS-LIKE PARTICLES OF HUMAN RESPIRATORY SYNZYTIAL VIRUS (HRSV)
MX2018002728A (es) 2015-09-03 2018-09-05 Novavax Inc Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
US11235050B2 (en) 2015-10-29 2022-02-01 Emory University Chimeric RSV, immunogenic compositions, and methods of use
KR102136678B1 (ko) 2015-12-23 2020-07-22 화이자 인코포레이티드 Rsv f 단백질 돌연변이체
CN109069611B (zh) 2016-03-29 2022-11-04 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
WO2017174568A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f proteins
CN109311946A (zh) 2016-05-30 2019-02-05 扬森疫苗与预防公司 稳定化的融合前rsv f蛋白
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
WO2018005558A1 (en) 2016-06-27 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof

Also Published As

Publication number Publication date
BR112019020661A2 (pt) 2020-05-05
US20220169681A1 (en) 2022-06-02
AU2018249533C1 (en) 2023-10-12
CN110603262A (zh) 2019-12-20
US20200392187A1 (en) 2020-12-17
PH12019502276A1 (en) 2020-09-28
AU2022202787A1 (en) 2022-05-19
AU2018249533B2 (en) 2022-01-27
CN115779077A (zh) 2023-03-14
AU2018249533A1 (en) 2019-10-17
CN115947873A (zh) 2023-04-11
US11192926B2 (en) 2021-12-07
KR20190140916A (ko) 2019-12-20
CA3058794A1 (en) 2018-10-11
EP3606942A1 (en) 2020-02-12
MX2023004704A (es) 2023-05-09
WO2018187325A1 (en) 2018-10-11
US11732011B2 (en) 2023-08-22
MX2019011869A (es) 2020-01-09
IL269643A (en) 2019-11-28
JP2020515280A (ja) 2020-05-28
US20240150411A1 (en) 2024-05-09
JP2023002680A (ja) 2023-01-10
JP7168938B2 (ja) 2022-11-10
RU2019130167A (ru) 2021-05-05
SG11201908999QA (en) 2019-10-30

Similar Documents

Publication Publication Date Title
BR122021024397A2 (ru)
BR122021023687A2 (ru)
BR122022003522A2 (ru)
BR122022025811B8 (ru)
BR122021000189A2 (ru)
BR112019008823A2 (ru)
BR112020006084A8 (ru)
BR122021014832A2 (ru)
BR202018014992U2 (ru)
BR112020008820A2 (ru)
BR202017025154U2 (ru)
BR102017023327A2 (ru)
BR202017021228U2 (ru)
BR202017020981U2 (ru)
BR202017017068U2 (ru)
BR202017016984U2 (ru)
BR202017016924U2 (ru)
BR102017015495A2 (ru)
BR102017015250A2 (ru)
BR102017014430A2 (ru)
BR202017012548U2 (ru)
BR202017011220U2 (ru)
BR202017010814U2 (ru)
BR202017010373U2 (ru)
BR202017009870U2 (ru)